Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
378.25 | 61,311 Cr | 90.90 | 1.62 | 0.10 | 1.81 | 4.20 | 1.00 | |
662.05 | 37,449 Cr | 82.34 | 13.61 | 0.00 | 18.75 | 26.49 | 14.76 | |
400.35 | 16,132 Cr | 45.73 | 3.41 | 0.31 | 9.89 | 11.96 | 5.38 | |
1332.50 | 15,313 Cr | 770.96 | 2.59 | 0.00 | 2.34 | 3.64 | 0.25 | |
376.35 | 3,227 Cr | 18.19 | 2.30 | 0.00 | 10.96 | 10.33 | 4.37 | |
287.00 | 3,182 Cr | 21.11 | 2.14 | 1.83 | 9.93 | 14.10 | 9.17 | |
316.60 | 1,955 Cr | -263.83 | 2.37 | 0.00 | -5.71 | -5.58 | -0.65 |
Biocon Ltd (BIOCON) is currently trading at 389.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Biocon is a fully integrated, innovation‑led biopharmaceutical company from India focused on biosimilars, complex biologics, interchangeable insulins, generic formulations, peptides (GLP‑1s) and research/CRDMO services through Syngene with global manufacturing and commercialization reach across North America, Europe and emerging markets. The group is at an operational inflection: major capex is largely complete, operating leverage is beginning to play out, and management highlights margin expansion and cash‑flow led value creation as priorities while retaining significant R&D investment of about INR 249 crore in Q3 FY26. Biocon’s biosimilars franchise is accelerating commercial traction with multiple regulatory wins (MHRA, EMA approvals) and launches; the company lists roughly 17 oncology assets and cites an approximately US$75+ billion addressable opportunity in oncology and immunology, reflecting deliberate pipeline focus. Financially, Q3 FY26 showed resilience: consolidated operating revenue of INR 4,173 crore (up 9% YoY), core EBITDA growth of 21% YoY to INR 1,221 crore, biosimilars EBITDA up 44% YoY, and a reported net profit recovery driven by favorable mix, higher‑margin prioritization and balance sheet simplification.
Over the past 52 weeks, Biocon Ltd has traded between a low of ₹295.30 and a high of ₹424.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Biocon Ltd has a market capitalization of approximately 61,310.84. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Biocon Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 90.90 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 61,310.84 Cr, Biocon Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Biocon Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Biocon Ltd is 90.90. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Biocon received U.S. FDA approval for Liraglutide Injection, which will be marketed under the brand name gSaxenda®, for chronic weight management.
In Q3 FY26, Biocon reported a consolidated net profit of ₹143.8 crore, a significant increase from ₹25.1 crore in the previous year. Revenue from operations grew 9.2% to ₹4,173 crore, and EBITDA rose 21% to ₹951 crore.
It is a government initiative with a ₹10,000 crore outlay over five years to make India a global manufacturing hub for biologics and biosimilars, focusing on complex therapies for non-communicable diseases.
The Finance Minister proposed a Rs 10,000 crore investment in the biopharmaceutical sector, to be deployed over the next five years to boost manufacturing, research, and technology.
Bearish
1
Neutral
8
Bullish
5
Bearish
1
Neutral
8
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Analyst/Investor Meet
Biocon informed exchanges under Reg 30 that management will participate in JP Morgan's India Credit Investor Trip (virtual group meeting) on 11-Mar-2026; no UPSI will be disclosed.
Acquisition (Subsidiaries)
On March 3, 2026 Biocon Limited acquired 11,53,44,285 OCRPS (Rs.10 each; ~₹1,153.44 mn) in Biocon Biosphere Ltd and 20,00,00,000 OCRPS (Rs.10 each; ₹2,000.00 mn) in Biocon Pharma Ltd to fund working capital/capex.
Biocon is a fully integrated, innovation‑led biopharmaceutical company from India focused on biosimilars, complex biologics, interchangeable insulins, generic formulations, peptides (GLP‑1s) and research/CRDMO services through Syngene with global manufacturing and commercialization reach across North America, Europe and emerging markets.
The group is at an operational inflection: major capex is largely complete, operating leverage is beginning to play out, and management highlights margin expansion and cash‑flow led value creation as priorities while retaining significant R&D investment of about INR 249 crore in Q3 FY26.
Biocon’s biosimilars franchise is accelerating commercial traction with multiple regulatory wins (MHRA, EMA approvals) and launches; the company lists roughly 17 oncology assets and cites an approximately US$75+ billion addressable opportunity in oncology and immunology, reflecting deliberate pipeline focus.
Financially, Q3 FY26 showed resilience: consolidated operating revenue of INR 4,173 crore (up 9% YoY), core EBITDA growth of 21% YoY to INR 1,221 crore, biosimilars EBITDA up 44% YoY, and a reported net profit recovery driven by favorable mix, higher‑margin prioritization and balance sheet simplification.
Pharmaceuticals
Biotechnology
61,311 Cr
Moderate Risk
90.9
58.9
1.9
1.6
424.95
295.30
Sales CAGR
Profit CAGR
ROE
ROCE
